抽吸取栓与其他血管内治疗在近端上肢深静脉血栓中的比较
单中心回顾性研究纳入22例静脉胸廓出口综合征所致急性症状性近端上肢深静脉血栓患者,比较机械抽吸取栓(AT)与非抽吸取栓(NAT)技术,主要终点为技术成功(血栓溶解>70%)。全部患者均获技术成功,AT组单次治疗率50%,NAT组仅8.3%,AT组溶栓剂平均总剂量12.6±9.65 mg,NAT组19.0±5.78 mg。
要点
- AT组单次治疗完成率50%(5/10),NAT组仅8.3%(1/12)
- 全部22例患者技术成功,血栓溶解均>70%
- AT组溶栓剂平均总剂量12.6±9.65 mg,低于NAT组19.0±5.78 mg
核心结论
- 急性症状性近端UEDVT的血管内治疗技术成功率达100%。
- AT技术可提高单次治疗完成率,从而降低患者出血并发症风险。
- 尚需更多研究进一步明确该新技术在UEDVT治疗范式中的作用。
研究设计与样本
- 单中心回顾性研究,纳入2013年12月至2019年6月接受血管内治疗的急性症状性近端UEDVT患者22例。
- 患者均继发于静脉胸廓出口综合征,接受CDT、USAT、流变学取栓或AT等多种方法治疗。
- 比较AT组与非抽吸取栓(NAT)技术的结局,主要终点为技术成功(血栓溶解>70%)。
主要发现
- 全部22例患者(100%)均成功实现>70%的血栓溶解。
- AT组10例中50%(5/10)实现单次治疗,NAT组12例中仅8.3%(1/12)实现单次治疗。
- AT组溶栓剂平均总剂量为12.6±9.65 mg,NAT组为19.0±5.78 mg(平均差-6.4;95%CI -1.1至13.9)。
- AT组除1例外均成功完成第一肋切除术,NAT组全部成功完成第一肋切除术。
- 除1例外所有患者经锁骨下入路行第一肋切除,在DVT治疗中位8.0天(IQR 6.0-12.0)后移除肋骨。
关键数值与推荐
- 技术成功定义为血栓溶解超过70%。
- 次要终点为单次治疗完成能力。
临床怎么用
- 对于静脉胸廓出口综合征所致急性症状性近端UEDVT,AT可提高单次治疗完成率。
- AT可能通过减少溶栓剂用量降低出血并发症风险。
- 治疗后中位8.0天行第一肋切除术,多数经锁骨下入路。
局限性
- 单中心回顾性设计,样本量仅22例。
- AT组与NAT组样本量小且非随机分组,组间比较需谨慎解读。
- 减压时未行静脉造影评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Catheter-directed thrombolysis (CDT) provides an effective method for clearing deep venous thrombosis (DVT). Unfortunately, CDT is associated with hemorrhagic complications. This study evaluated the technical success of the various endovascular therapies including a new mechanical aspiration thrombectomy (AT) device for the treatment of acute upper extremity DVT (UEDVT). METHODS: This single-center retrospective review included patients with acute symptomatic proximal UEDVT secondary to venous thoracic outlet syndrome. Undergoing endovascular therapy from December 2013 to June 2019. Patients were treated with a variety of methods including CDT, ultrasound-assisted thrombolysis (USAT), rheolytic thrombectomy, and AT. We evaluated outcomes for patients undergoing AT compared with nonaspiration thrombectomy (NAT) techniques. The primary outcome was technical success, defined as resolution of more than 70% of the thrombus. The secondary end point was the ability to complete the therapy in a single session. RESULTS: There were 22 patients who had endovascular management of their symptomatic proximal UEDVT. All 22 patients (100%) were successfully treated with more than a 70% thrombus resolution. Ten patients underwent AT, of which 50% (5/10) had single session therapies. Twelve patients underwent NAT (three had CDT or USAT alone; three had USAT with rheolytic thrombectomy; and six had CDT followed by rheolytic thrombectomy), with single session therapy occurring in only 8.3% of the NAT group (1/12). The average total dose of thrombolytics was 12.6 ± 9.65 mg in the AT group compared with 19.0 ± 5.78 mg in the NAT group (mean difference, -6.4; 95% confidence interval, -1.1 to 13.9). All but one of the patients in the AT group went on to have successful first rib resections. All NAT patients had successful first rib resections. A venogram was not performed at the time of decompression. All patients except one underwent resection via the infraclavicular approach, with rib removal posterior to the brachial plexus, a median of 8.0 (interquartile range, 6.0-12.0) days after DVT therapy. CONCLUSIONS: In this study, a technical success rate of 100% was achieved for acute symptomatic proximal UEDVT therapies. AT technology allows for higher rates of treatment in a single session, thereby minimizing a patient's risks of bleeding complications. More research is needed to further define the role of this new technology in the treatment paradigm of UEDVT management.
引用
- Fuller T, Neville E, Shapiro J, et al. Comparison of aspiration thrombectomy to other endovascular therapies for proximal upper extremity deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34438088. doi:10.1016/j.jvsv.2021.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。